We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Macrophage Role in Infection Determined by PI-3 Kinase-Gamma Signaling

By LabMedica International staff writers
Posted on 29 Sep 2016
Cancer researchers have identified a molecule responsible for the signal that converts macrophages from an inflammatory, immunostimulatory mode in acute infections to an anti-inflammatory, immunosuppressive mode that supports tumor development and growth.

Macrophages play critical, but opposite, roles in acute and chronic inflammation and cancer. More...
In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T-cells, while highly abundant macrophages in cancer and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote tumor growth.

Investigators at the University of California, San Diego (USA) reported in the September 19, 2016, online issue of the journal Nature that results of experiments carried out with mouse models had allowed them to identify the macrophage enzyme PI-3 kinase-gamma (PI3K-gamma) as the controller of a critical switch between immune stimulation and suppression during inflammation and cancer.

PI3K-gamma signaling induced a transcriptional program that promoted immune suppression during inflammation and tumor growth. In contrast, selective inactivation of macrophage PI3K-gamma promoted an immunostimulatory transcriptional program that restored CD8+ T-cell activation and cytotoxicity and synergized with checkpoint inhibitor therapy to promote tumor regression and extend survival in mouse models of cancer.

“Immunotherapies, such as T-cell checkpoint inhibitors, are showing great promise in early treatments and trials, but they are not universally effective,” said senior author Dr. Judith A. Varner, professor of pathology and medicine at the University of California, San Diego. “We have identified a new method to boost the effectiveness of current immune therapy. Our findings also improve our understanding of key mechanisms that control cancer immune suppression and could lead to the development of more effective immunotherapies.”

Related Links:
University of California, San Diego


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: (a) CTC separation using contraction-expansion inertial microfluidics. (b) CTC detection using the YOLOv8 deep learning model. (Image Credit: Junyi Ouyang, Haiqin Li)

Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis

Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more

Molecular Diagnostics

view channel
Image: Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus test in Abbott’s screening portfolio, which now spans both stool‑ and blood‑based options (Photo courtesy of Freenome)

Blood-Based Test Broadens Colorectal Cancer Screening Options

Colorectal cancer is the second-leading cause of cancer-related death in the U.S., yet outcomes improve markedly when the disease is detected through routine screening. Despite this, up to 60 million Americans... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.